Why the study?
NOAC monotherapy has been suggested as the optimal antithrombotic therapy for AF beyond one year after coronary revascularization, but real-world comparative outcomes against NOAC plus antiplatelet combination therapy needed evaluation.
Does NOAC monotherapy improve outcomes and reduce bleeding in patients with atrial fibrillation beyond one year after coronary revascularization compared to NOAC plus antiplatelet combination therapy?
Does NOAC monotherapy improve outcomes and reduce bleeding in patients with atrial fibrillation beyond one year after coronary revascularization compared to NOAC plus antiplatelet combination therapy?
In patients with atrial fibrillation beyond one year after coronary revascularization, NOAC monotherapy provides similar ischemic protection with less major bleeding compared to NOAC plus antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
May support NOAC monotherapy to reduce bleeding without excess MACCE in AF >1 year post-revascularization; leaves open need for RCT confirmation.
BACKGROUND: Currently, non-vitamin K-antagonist oral anticoagulant (NOAC) monotherapy has been suggested as the optimal antithrombotic therapy for atrial fibrillation (AF) beyond one year after coronary revascularization. The aim of this study was to compare the outcomes between NOAC monotherapy and NOAC plus antiplatelet combination therapy using real-world data. METHODS: Between 2015 and 2020, patients with AF who had received NOACs beyond one year after coronary revascularization were enrolled from Korean national insurance data. We emulated a pragmatic sequence of trials between the NOAC monotherapy and the antiplatelet combination therapy followed by propensity score matching. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCEs), a composite of all-cause death, myocardial infarction, and stroke. CONCLUSION: As an antithrombotic therapy for AF beyond one year after coronary revascularization, NOAC monotherapy was associated with a similar risk of MACCE and a lower risk of major bleeding compared to NOAC plus antiplatelet combination therapy.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: